RIBER 15.360 € (+16,54 %)
NN GROUP 75.840 € (+0,42 %)
VALLOUREC 24.040 € (-0,33 %)
RELX 28.380 € (-0,77 %)
DBV TECHNOLOGIES 3.182 € (-0,44 %)
SAINT GOBAIN 75.280 € (+1,67 %)
TIKEHAU CAPITAL 17.900 € (+2,52 %)
COFACE 16.440 € (+0,80 %)
UNIBAIL-RODAMCO-WE 97.600 € (-0,06 %)
WENDEL 88.900 € (+0,91 %)
LVMH 472.600 € (-0,20 %)
STMICROELECTRONICS 57.930 € (+5,17 %)
OPMOBILITY 15.300 € (+2,20 %)
GECINA 72.350 € (-0,48 %)
AIR FRANCE -KLM 10.255 € (+1,64 %)
ABN AMRO BANK N.V. 33.940 € (+1,65 %)
BASIC-FIT 29.900 € (-0,33 %)
DSM FIRMENICH AG 71.500 € (+0,25 %)
GTT 204.800 € (+0,59 %)
ADYEN 957.900 € (+1,58 %)
AMUNDI 85.700 € (-0,12 %)
METROPOLE TV 11.500 € (-0,17 %)
CARREFOUR 17.090 € (-1,07 %)
IPSEN 160.200 € (-0,25 %)
SODEXO 45.640 € (+0,13 %)
NOVACYT 0.580 € (+0,87 %)
ID LOGISTICS GROUP 362.500 € (-0,41 %)
ROCHE BOBOIS 25.600 € (-3,40 %)
ATOS 43.680 € (+7,22 %)
SES 8.950 € (+1,36 %)
2CRSI 46.700 € (+3,73 %)
NANOBIOTIX 36.460 € (+8,77 %)
FORVIA 10.375 € (+3,13 %)
AMG 38.640 € (+3,76 %)
SHELL PLC 37.110 € (-0,92 %)
AIRBUS 169.520 € (+2,15 %)
TRIGANO 153.600 € (-0,07 %)
BNP PARIBAS ACT.A 89.930 € (+0,86 %)
VIEL ET COMPAGNIE 18.900 € (+0,11 %)
ASR NEDERLAND 65.760 € (+1,20 %)
AALBERTS NV 38.760 € (+3,75 %)
REMY COINTREAU 40.600 € (-0,93 %)
VALEO 12.640 € (+2,39 %)
VICAT 61.800 € (+1,98 %)
ABIVAX 105.900 € (+0,76 %)
TOTALENERGIES 78.650 € (-2,01 %)
TELEPERFORMANCE 72.200 € (-1,45 %)
EKINOPS 3.100 € (+8,01 %)
ASML HOLDING 1 409.000 € (+4,74 %)
MERCIALYS 11.960 € (0,00 %)
QUADIENT 12.340 € (+3,01 %)
ALTEN 62.850 € (+1,05 %)
BILENDI 13.800 € (+0,29 %)
PHILIPS KON 23.370 € (+0,65 %)
CRCAM SUD R.A.CCI 245.500 € (+0,61 %)
AXA 40.120 € (+0,02 %)
KAUFMAN ET BROAD 25.050 € (+1,01 %)
WOLTERS KLUWER 62.500 € (-0,83 %)
L'OREAL 361.650 € (+0,61 %)
DANONE 61.860 € (-1,59 %) |
20/05/2026 14:05
NCCN Affirms Commitment to Cancer-Related Distress Resources Worldwide During Mental Health Awareness MonthEQS-News: National Comprehensive Cancer Network / Key word(s): Miscellaneous/Miscellaneous The latest version of the National Comprehensive Cancer Network's Distress Thermometer and Problem List is available for free in more than 70 languages. PLYMOUTH MEETING, Pa., May 20, 2026 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—announces that the latest version of the NCCN Distress Thermometer and Problem List, a rapid validated screening tool (0-10 scale) is available in more than 70 languages to identify and address patient distress. Cancer care providers can quickly and effectively screen patients for mental, physical, social, or spiritual concerns that may make it harder to cope with having cancer, its symptoms, or its treatment using this one-page tool. ![]() People worldwide can visit NCCN.org/distress-thermometer for free access to the NCCN Distress Thermometer Screening Tool in available languages. NCCN also provides free resources to guide care providers on managing distress, as well as a newly-updated version for patients and caregivers with easy-to-understand language, pictures, and glossary, thanks to funding from the NCCN Foundation®. "Mental Health Awareness Month, every May, serves as an important reminder of how social-emotional wellbeing can impact people with cancer," said Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. "High-quality cancer care means treating the entire person, identifying and addressing any practical or psychological concerns that come up. We keep the NCCN Distress Thermometer and Problem List current in dozens of different languages to help ensure everyone has access to the support they need." The Distress Thermometer was downloaded nearly 7,000 times around the world in 2025, most-frequently in Germany, Brazil, India, China, and Switzerland. A research abstract presented during the NCCN 2026 Annual Conference, and now available at JNCCN.org, by Babayan et. al., validated the translated NCCN Distress Thermometer as a helpful and culturally-appropriate tool for identifying psychological distress in Armenian-speaking patients. The findings support integrating its use in order to enhance cancer care. The NCCN Distress Thermometer was previously confirmed to be an effective gauge for distress through an independent, peer-reviewed study across 25 countries, published in Psycho-Oncology in 2022. The full list of languages available, in addition to English, include:
* Indicates multiple versions of the language available. The NCCN Distress Thermometer is a key element of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Distress Management. It is part of a comprehensive library of evidence-based, expert consensus-driven guidelines maintained by more than 2,000 multidisciplinary specialists covering many types of cancer, as well as topics like pain, fatigue, smoking cessation, and survivorship. There are currently 91 NCCN Guidelines® in all, featuring best practices for supportive care, plus screening, prevention, and treatment for nearly every type of cancer. There are more than 90 global adaptations of the NCCN Guidelines and over 180 translations, with nearly half of all registered users for NCCN.org based outside the United States. Learn more about NCCN's various resources for improving international cancer care by visiting NCCN.org/global. About the National Comprehensive Cancer Network Media Contact: ![]() Photo - https://mma.prnewswire.com/media/2980644/NCCN_Distress_Thermometer_Web_Ads_Infographic.jpg Logo - https://mma.prnewswire.com/media/441768/NCCN_Logo_Updated.jpg
![]() 20.05.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. 2330694 20.05.2026 CET/CEST Source : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière


